Search results

1729 results

Sorted by Relevance . Sort by Date

  1. Postnatal care

    In development [GID-NG10070] Expected publication date: 07 April 2021

  2. Acute coronary syndromes

    In development [GID-NG10085] Expected publication date: 18 November 2020

  3. Shared decision making

    In development [GID-NG10120] Expected publication date: 17 June 2021

  4. Antenatal care

    In development [GID-NG10096] Expected publication date: 11 August 2021

  5. Acne Vulgaris: Management

    In development [GID-NG10109] Expected publication date: 09 June 2021

  6. Caesarean section (update)

    In development [GID-NG10081] Expected publication date: 31 March 2021

  7. Inducing labour (update)

    In development [GID-NG10082] Expected publication date: 14 October 2021

  8. Diabetes update

    In development [GID-NG10152] Expected publication date: TBC

  9. Pernicious anaemia

    In development [GID-NG10176] Expected publication date: 23 March 2023

  10. Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (TA429)

    Evidence-based recommendations on ibrutinib (Imbruvica) for treating chronic lymphocytic leukaemia in adults

  11. Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)

    Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults

  12. Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)

    Evidence-based recommendations on dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant/intolerant chronic myeloid leukaemia in adults

  13. Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)

    Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive breast cancer that is locally advanced, inflammatory, or early-stage with a

  14. Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

    Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic breast cancer after 2 or more types of chemotherapy

  15. Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)

    Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults

  16. Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

    Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy

  17. Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)

    Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events such as heart attacks or stroke after myocardial infarction (MI)